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Loss  aversion,  a well-documented  behavioral  phenomenon,  characterizes  decisions  under
risk in  adult  populations.  As  such,  loss  aversion  may  provide  a reliable  measure  of  risky
behavior.  Surprisingly,  little is  known  about  loss aversion  in adolescents,  a group  who
manifests  risk-taking  behavior,  or in anxiety  disorders,  which  are  associated  with  risk-
avoidance.  Finally,  loss  aversion  is expected  to  be modulated  by  genotype,  particularly  the
serotonin transporter  (SERT)  gene  variant,  based  on its role  in  anxiety  and impulsivity.  This
genetic  modulation  may  also  differ between  anxious  and  healthy  adolescents,  given  their
distinct  propensities  for  risk  taking.  The  present  work  examines  the  modulation  of  loss
aversion,  an  index  of  risk-taking,  and  reaction-time  to decision,  an  index  of impulsivity,  by
the serotonin-transporter-gene-linked  polymorphisms  (5HTTLPR)  in  healthy  and  clinically
anxious  adolescents.  Findings  show  that  loss  aversion  (1) does  manifest  in adolescents,  (2)isk-avoidance does not  differ  between  healthy  and  clinically  anxious  participants,  and  (3),  when  stratiﬁed
by SERT  genotype,  identiﬁes  a subset  of  anxious  adolescents  who  are  high  SERT-expressers,
and  show  excessively  low  loss-aversion  and high  impulsivity.  This  last  ﬁnding  may  serve
as  preliminary  evidence  for 5HTTLPR  as a risk  factor  for the  development  of  comorbid
disorders  associated  with  risk-taking  and impulsivity  in  clinically  anxious  adolescents.
The Au©  2013 
. Introduction
Loss aversion is a classical concept in behavioral
conomics (Kahneman and Tversky, 1979). Indeed, a
rominent theoretical account of economic decision-
aking, Prospect Theory (Kahneman and Tversky, 1979),
ndicates that people are more sensitive to losses than
ains, typically by a factor of two (Novemsky and
ahneman, 2005). Loss aversion is traditionally measured
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using a series of mixed gambles that vary in magnitude
of potential gains and losses. It is computed as the ratio
(lambda) of the contribution of loss magnitude to that of
gain  magnitude to the subject’s decision (e.g., Tom et al.,
2007).  This mathematically modeled, extensively studied
behavioral characteristic appears highly reliable in adults.
It  captures an aspect of risk-avoidance and, its converse,
risk-taking, both, of which are particularly relevant to ado-
lescence  and anxiety.
Adolescence is a unique time in life, when developmen-
tal factors might have opposing effects on loss aversion. On
the  one hand, adolescents experience a peak in their risk-
taking  behavior (Spear, 2000), which, at face value, could
Open access under CC BY-NC-ND license.be  associated with low levels of loss aversion (Kahneman
and Lovallo, 1993). Thus, adolescence might be expected
to  signal low levels of loss aversion. On the other hand,
adolescence also is a time when anxiety increases, and
  
NC-ND license.
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Table 1
Distribution of diagnoses (a) in the anxious adolescents as a whole and
(b) by genotype. As expected based on comorbid anxiety disorders, the
total numbers of diagnoses exceed the size of each sample. For example,
the high-expresser sample includes 9 subjects, while the total number
of diagnoses amount to 11. Two high-expresser subjects had 2 anxiety
diagnoses. GAD, Generalized Anxiety Disorder; SocPh, Social Phobia; SAD,
Separation Anxiety Disorder.
(a)
Total Comorbidity
GAD 16 GAD-only 12
GAD/SAD/SocPh 2
GAD/SAD 2
SocPh  7 SocPh-only 4
Soc-Ph/SAD 1
SAD  11 SAD-only 6
(b)
Patients GAD SocPh SAD78 M. Ernst et al. / Developmental 
prior research links anxiety to risk avoidance (Lorian and
Grisham,  2010; Maner et al., 2007; Mueller et al., 2010),
which could be associated with high levels of loss aver-
sion.  Taken together, these two sets of contrasting ﬁndings
raise  major questions on the way in which loss aversion
manifests in adolescents, in general, as well as in adoles-
cents with high levels of anxiety. At present, only one study
has  compared loss aversion in adolescents and adults, and
this  study failed to detect differences in the measure of
loss  aversion, lambda, between these age groups (Barkley-
Levenson et al., 2013). No studies have yet assessed the
relationship between loss aversion and anxiety at any age.
Finally,  anxiety is a heterogeneous set of clinical con-
ditions, showing variable relationships to environmental
risks, such as stress or trauma, and genetic factors. Particu-
lar  interest has arisen concerning the relationship between
anxiety and variation in the serotonin transporter (SERT)
gene  (Bengel et al., 1999; Gonda et al., 2009; Lesch et al.,
1996;  Sen et al., 2004). Understanding the contribution of
genotype  to anxiety is important because genetics may
moderate relationships between anxiety and its neurobi-
ological correlates (e.g., Pine et al., 2010; Xu et al., 2006).
Accordingly, SERT variants could also moderate the rela-
tion  of anxiety with loss aversion, a relation which, in the
future,  could be captured at the neural level in follow-up
studies using functional neuroimaging tools.
This study tests four hypotheses. We  expect that (1) ado-
lescents would exhibit some degree of loss aversion, since
loss  aversion is a well-established phenomenon across
adult populations (Novemsky and Kahneman, 2005); (2)
Loss  aversion would be higher in clinically anxious com-
pared  to healthy adolescents; (3) Loss aversion would be
inﬂuenced  by SERT gene variants. Speciﬁcally, we  expect
that  high-expressers (LaLa carriers) would show lower lev-
els  of loss aversion based on the role of this gene variant in
impulsive-related behaviors (e.g., Beitchman et al., 2003;
Curran  et al., 2005; Manor et al., 2001; Retz et al., 2008,
2002; Seeger et al., 2001; Zoroglu et al., 2002), relative to
low-expressers (S/Lg carriers) who would manifest higher
levels  of loss aversion based on the role of this gene variant
in  anxiety and harm avoidance (e.g., Bengel et al., 1999;
Gonda et al., 2009; Lesch et al., 1996; Sen et al., 2004).
Similarly, we anticipate differences in reaction time to
execute  a decision involving risky options, such that fast
reaction  time, indicative of impulsivity, would character-
ize  low loss-averse individuals, whereas long reaction time
would  characterize high loss-averse individuals. Finally, (4)
we  expect that genotype would moderate the relationship
between anxiety and loss aversion (lambda), emerging in
an  interaction between diagnosis and genotype.
2. Methods
2.1. Participants
A  total of 66 Caucasian adolescents, 27 with an anxiety
disorder and 39 healthy comparisons were assessed on the
Loss  Aversion task, a paradigm of mixed monetary gambles
(Tom  et al., 2007). Most patients carried more than one
anxiety disorder, as delineated in Table 1. In addition, ﬁveHigh expressers (n = 9) 4 (44.4%) 1 (11.1%) 6 (66.7%)
Low expressers (n = 18) 12  (66.7%) 6 (33.3%) 5 (27.8%)
patients met  another non-anxiety comorbid diagnosis (see
Table  1).
Participants were recruited through local newspaper
advertisements and word of mouth, and the study was
approved by the National Institute of Mental Health Insti-
tutional Review Board. The group of anxious adolescents
was  recruited for a treatment study of anxiety, and the
comparisons were recruited from the same community. For
the  participants enrolled in the treatment study of anxiety,
the  task was  completed during an initial research period
prior  to treatment entry. The parents of all children gave
informed consent, and minors gave informed assent.
Inclusion criteria for comparisons comprised (1) age
between 8 and 17 years; (2) absence of acute or chronic
medical problems; and (3) absence of current or past psy-
chiatric  disorders. Inclusion criteria for anxious youths
included: (1) primary diagnosis of an anxiety disorder
based on a semi-structured diagnostic interview (K-SADS;
Kaufman et al., 1997) completed by a trained clinical
psychologist; (2) desire for outpatient treatment; (3) age
between  8 and 17 years. Exclusion criteria for all partic-
ipants consisted of (1) current use of any psychoactive
substance; (2) current Tourette’s syndrome, obsessive-
compulsive disorder, PTSD, conduct disorder, exposure to
extreme  trauma, or suicidal ideation; (3) lifetime history of
mania,  psychosis, or pervasive developmental disorder; or
(4)  IQ < 70.
2.2. Assessment tools and genotyping
IQ was measured using the vocabulary and matrix
reasoning subscales of the Wechsler Abbreviated Scale of
Intelligence  (WASI; Weschler, 1999). Socioeconomic status
was  obtained through parental report and calculated based
on  Hollingshead’s index of social position for education and
Hollingshead’s categories for employment (Hollingshead,
1975). The parent and child version of the Screen for Child
Anxiety Related Emotional Disorders (SCARED; Birmaher
et  al., 1997; Muris et al., 1999) were collected, and the
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verage scores for parent and child SCARED were used as
he  index of anxiety severity (SCAREDpc).
DNA extraction and genotyping for this sample was con-
ucted  according to published procedures (Hu et al., 2006).
enomic  DNA was prepared from laboratory-collected
aliva samples using Oragene DNA kits (DNA genotek,
ttowa, Ontario, Canada), or, when available, blood sam-
les.  The SLC6A4 promoter (5HTTLPR) genotyping was
erformed in two stages using size discrimination for the
 (103 bp), L (146 bp), La (146 bp) and Lg (61 bp) alleles.
he 5HTTLPR region was ampliﬁed in a 20 l reaction: 1×
ptimized Buffer A, 1× PCR enhancer, 0.25 M each primer
FAM-ATCGCTCCTGCATCCCCCATTAT (forward), GAGGT-
CAGGGGGATGCTGGAA (reverse)], 0.125 M dNTP, 10 ng
NA,  1.25 Platinum Taq polymerase (all Invitrogen Corp);
5 ◦C (5 min), 40 cycles of 94 ◦C (30 s), 52 ◦C (30 s), 68 ◦C
1  min), and a ﬁnal elongation, 68 ◦C (10 min). S and L geno-
ypes  were discriminated directly from the PCR reaction
roducts, rs25531 genotype was determined by digesting
0  l PCR mix  with 100 units MspI (37 ◦C, 1 h, 1× restriction
uffer). Samples were mixed with deionized formamide
nd GeneScanTM-500 ROX Size Standard (Applied Biosys-
ems), and genotypes resolved on a 3730 DNA Analyzer
Applied Biosystems).
Variation at the closely linked SNP rs25531 also
odulates SLC6A4 expression, with the relatively com-
on  Lg allele having a similar expression proﬁle to
he  S allele (Hu et al., 2006). As such, participants
ere assigned to one of two groups based on the
resumed neurotransmitter expression level. For the cur-
ent  study, “high-expressers” will refer to those with
he  LaLa-allele and “low-expressers” will refer to those
ith  SLa, SLg, and SS-alleles (S/Lg). In this sample
1 (9 anxious and 12 healthy) subjects were high-
xpressers and 45 (18 anxious and 27 healthy) were
ow-expressers.
.3. Task description
Participants completed a computerized betting task in
hich  they were asked to either take or reject a 50/50
hance to win one amount of money or lose another
mount of money, similar to a coin toss (Tom et al.,
007). Based on the notion that losses loom larger than
ains  (Tversky and Kahneman, 1992), gains were scaled
etween $10 and $40 by increments of $2, and losses
ere scaled between $5 and $20 by increments of $1. All
ombinations between potential gain and potential loss
alues  were presented in a random order (256 total gam-
les).
In  order to assess individual differences in the level of
ttractiveness of each bet, as well as to discourage par-
icipants from establishing a set response pattern while
laying, 4 response options were offered to the partici-
ants. Participants could choose to (1) strongly take, (2)
eakly  take, (3) strongly pass or (4) weakly pass on each
f  the gambles presented. Feedback was not provided and
he  task was self-paced. Participants were told that at the
ompletion of the game, three randomly chosen gambles
ould determine their compensation or loss. For each bet
hey  chose to “take” whilst playing the game, they were tolde Neuroscience 8 (2014) 77–85 79
that  an actual coin toss would establish if they won or lost
money.  If they chose to “pass” on the bets, no money would
be  added or subtracted from their total compensation. At
the  end of the task, subjects were told the cumulative
amount of money they would have won or lost from 3
random  bets.
2.4.  Statistical analyses
We  computed a behavioral index of loss aversion
(lambda) by ﬁtting a logistic regression to each partici-
pant’s responses collected during the task with sizes of gain
and  loss used as independent variables. Lambda was calcu-
lated  as the ratio of the absolute loss response to the gain
response (Tom et al., 2007).
Reaction  time (RT) was calculated on valid trials. Invalid
RT  was  deﬁned as RT < 150 ms  or >2.5 SDs above the mean
(e.g.,  impulsive responses or initial inattention to the cue).
There  was an average of 5.7 (SD = 1.9) outliers per sub-
ject  (out of 256 trials) across the whole sample, and the
average number of outliers did not differ across geno-
type groups (F = 3.0, df = 1,61, p = 0.08) or diagnostic groups
(F  = 0.97, df = 1,61, p = 0.39). The range was within what
could be expected for executing a decision on a guessing
task. Decision-making tasks usually allow 3000 ms  for exe-
cuting  a selection between numerical options (e.g., Tom
et  al., 2007; Barkley-Levenson et al., 2013; Eshel et al.,
2007).
Given  the differences in sample size, we  used the Lev-
ene’s test to test for homogeneity of lambda variance across
groups.  Variance did not differ between diagnostic groups
(F  = 0.54, df = 1,64, p = 0.47) or genotype groups (F = 1.82,
df  = 1,64, p = 0.19). Therefore, no correction procedure was
necessary.
We  used a 2-way ANOVA to examine the effects and
interaction of Diagnosis (anxious, comparison) and Geno-
type  (high-expressers, low-expressers) on demographic
variables to identify potential confounders. The only poten-
tial  confounder was age, which was correlated with lambda
(see  results). Therefore, all analyses were controlled for
age.  However, for completeness, we also show the results
without controlling for age. Lambda (measure of loss aver-
sion)  and reaction time (RT) to bet or pass were analyzed
using 2-way ANCOVAs, with Diagnosis and Genotype as
the  between-subjects factors, and age as the covariate of
nuisance.
In  addition, analyses were also conducted after cor-
recting not only for age but also for differences in RT.
Finally, anxiety scores (SCAREDpc) were also used as com-
plementary analyses to examine the effects of anxiety as a
continuous  variable instead of using the categorical vari-
able  of Diagnosis.
3.  Results
3.1. DemographicsTable 2 summarizes the description of the demographic
variables as a function of Diagnosis and Genotype. The only
demographic that differed between groups was age. The
anxiety  patients (M = 11.50, SD = 2.53) were younger than
80 M. Ernst et al. / Developmental Cognitive Neuroscience 8 (2014) 77–85
Table  2
Demographic and clinical characteristics of the sample by Diagnosis and Genotype (A-LaLa, anxious high-expressers; A-S/Lg, anxious low-expressers;
H-LaLa,  healthy high-expressers; H-S/Lg, healthy low-expressers).
Statistics (p values)
A-LaLa A-S/Lg H-LaLa H/S/Lg Diagnosis Genotype Diag.*Genotype
N 9 18 12 27
Male/female  4/5 8/10 5/7 14/13 NS NS NS
Age mean (SD) 11.0 (2.4) 11.7 (2.6) 14.3 (2.7) 12.6 (2.3) 0.003 NS NS
IQ  mean (SD) 115.1  (12.3) 114.4  (11.8) 108.8  (11.5) 117.9  (10.7) NS  NS NS
SES mean (SD) 37.6 (17.7) 29.5  (9.4) 35.2  (9.8) 34.5  (14.8) NS NS NS
7.5
(mean = 2098.9 ms,  SD = 543.1). Since this pattern was  sim-
ilar  among the genotype groups as well as among the
diagnostic groups, type of decision (bet, pass) was  not used
as  a factor in the subsequent analyses.
Table 3
Mean  (SD) reaction time by Genotype and Diagnosis (A-LaLa, anxious
high-expressers; A-S/Lg, anxious low-expressers; H-LaLa, healthy high-
expressers; H-S/Lg, healthy low-expressers).Comorbid non-anxiety Diagnoses MDD n = 1
ADHD n = 1
ADHD n = 1
ODD n = 2
SCAREDpc mean (SD) 30.6 (19.6) 29.9 (5.9) 
the healthy adolescents (M = 13.10, SD = 2.54). There were
no  age differences as a function of genotype status.
As expected, the SCAREDpc scores were signiﬁcantly
higher in the anxious than the healthy group.
3.2. Lambda (loss aversion)
Lambda  across the whole group was positive with an
average of 1.39 (SD = 0.80) which was signiﬁcantly differ-
ent  from zero (p < 0.0001). Lambda was not modulated by
gender,  IQ, SES or SCAREDpc across the whole sample.
However, lambda was positively correlated with age
in  the whole group (r = 0.37, F = 4.32, df = 1,63, p = 0.04).
This correlation remained signiﬁcant after controlling for
Diagnosis  or Genotype (F = 4.49, df = 1.62, p = 0.019). As age
increased  across the sample, loss aversion also increased.
We  examined whether the effect of age on lambda
was moderated by Genotype or Diagnosis. Regarding
Genotype, lambda was modulated differently by age
in  high-expressers vs. low-expressers (age*genotype:
F = 4.98, df = 1,64, p = 0.029). Lambda increased with age in
the  high expressers (LaLa: r = 0.63, p = 0.002, n = 21), but
was  not inﬂuenced by age in the low-expressers (S/Lg:
r  = 0.04, p = 0.81, n = 45). As a reminder, the age distribu-
tion was similar in both genotype groups (t(64) = 0.95,
p  = 0.345). Regarding Diagnosis, diagnostic group showed
a  trend effect on the relationship of lambda with
age (age*Diagnosis: F = 0.3, df = 1,64, p = 0.09). Lambda
increased with age in both diagnostic groups, signiﬁcantly
so in healthy adolescents (F = 6.03, df = 1,37, p = 0.019),
and not signiﬁcantly so in anxious adolescents (F = 0.82,
df  = 1,25, p = 0.37).
A two-way ANCOVA tested main effects and interac-
tions of Diagnosis and Genotype on lambda with age as the
nuisance  covariate. Results revealed no main effect of Diag-
nosis  (F = 1.01, df = 1,61, p = 0.32), indicating that clinically
anxious adolescents did not differ from healthy adoles-
cents on lambda (anxious: mean = 1.30, SD = 1.03; healthy:
mean = 1.47, SD = 0.59). However, the Diagnosis by Geno-
type  interaction was statistically signiﬁcant, F (1,61) = 5.78,
p  = .019 (see Fig. 1). Genotype also showed a main effect
on  lambda (F = 5.2, df = 1,61, p = 0.027). This effect indicated
that  lambda was lower in high-expressers (LaLa-allele:
lambda lsmeans 1.09) than low-expressers (S/Lg-allele:
lambda lsmeans 1.54).
Findings  were similar when not correcting for age (two-
way  ANOVA): Genotype had a main effect on lambda (7.1) 6.7 (6.0) <0.0001 NS NS
(F  = 4.24, df = 1,62, p = 0.04) characterized by lower lambda
in  high-expressers (LaLa-Lambda, mean = 1.2, SD = 1.0)
than  low-expressers (S/Lg-lambda mean = 1.5, SD = 0.66). In
addition,  Diagnosis by Genotype interaction on lambda was
highly  signiﬁcant (F = 8.14, df = 1,62, p = 0.006), and there
was  a trend for Diagnosis to inﬂuence lambda (anxious:
lambda mean = 1.3 SD = 1.02; healthy: lambda mean = 1.5,
SD  = 0.59; F = 3.15, df = 1,62, p = 0.08).
The  two-way ANCOVA was decomposed into 2 one-way
ANCOVAs to examine the effect of Genotype on lambda in
the  anxiety group and the healthy group separately. Geno-
type  had a signiﬁcant effect on lambda in the anxious group
(F  = 5.96, df = 1, 24, p = 0.02). Anxious adolescents who
were high-expressers (LaLa, M = 0.64, SD = 1.26) had lower
lambda  scores than anxious adolescents who were low-
expressers (S/Lg, M = 1.62, SD = .73). Healthy children did
not  differ on lambda scores by Genotype (high-expressers:
M = 1.57, SD = .54; low-expressers: M = 1.41, SD = .61, F = 0.0,
df  = 1,36, p = 0.96; see Fig. 1).
Complementary analyses were run using anxiety sever-
ity  (SCAREDpc scores) as a continuous variable instead
of  the categorical variable Diagnosis. The correlations
between lambda and SCAREDpc differed signiﬁcantly
between genotypes (F = 4.2, df = 1,61, p = 0.045). The high-
expresser group showed a negative correlation between
lambda and SCAREDpc (r = −0.39, p = 0.08, n = 21) (Fig. 2a),
whereas the low-expresser showed a non-signiﬁcant pos-
itive  association (r = 0.18, p = 0.22, n = 45) (Fig. 2b).
3.3. Reaction time (RT)
Mean  (SD) RTs are listed in Table 3. Across the whole
sample, RT was  shorter (F = 19.6 df = 1,61, p < .001) for bet-
taking  (mean = 1800.8 ms,  SD = 470.5) than bet-rejectingA-LaLa A-S/Lg H-LaLa H-S/Lg
N 9 18 12 27
Mean (ms) 1573.3 2020.3 1812.2 1876.8
SD 515.519 525.417 491.116 394.987
M. Ernst et al. / Developmental Cognitive Neuroscience 8 (2014) 77–85 81
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
A-LaLa A-S/Lg H-LaLa H-S/Lg
rLamb da
A-LaLa
A-S/Lg
H-LaLa
H-S/Lg
Fig. 1. Mean (standard error) of lambda (residuals after age correction, r-lambda) in the anxious and healthy groups by genotype (A-LaLa, anxious high-
expressers;  A-S/Lg, anxious low-expressers; H-LaLa, healthy high-expressers; H-S/Lg, healthy low-expressers).
Fig. 2. Correlation plots between lambda and SCAREDpc by genotype: (a) high-expressers (LaLa) show a negative correlation between anxiety severity
and  lambda: the more anxious, the less loss-averse individuals tended to be if they were high expressers; and (b) low-expressers (S/Lg) show a positive
non-signiﬁcant correlation between anxiety severity and lambda.
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rRT
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ection, 
xpresseFig. 3. Mean (standard error) of reaction time (residuals after age corr
high-expressers; A-S/Lg: anxious low-expressers; H-LaLa: healthy high-e
A 2-way ANCOVA with age as a nuisance covari-
ate was used to examine the effects of Diagnosis and
Genotype on RT. The interaction of Diagnosis by Geno-
type  was signiﬁcant (F = 4.82, df = 1,61, p = 0.03). This
interaction reﬂected shorter RT in low- than high-
expressers in the patient group, and no RT difference
by genotype in the healthy group (RT lsmeans in
ms:  anxious-LaLa = 1502.6, anxious-S/Lg = 1985.5, healthy-
LaLa  = 1904.4, healthy-S/Lg = 1882.7) (see Fig. 3). There was
a  trend for a main effect of Genotype (F = 2.8, df = 1,61,
p  = 0.09). The main effect of Diagnosis was not signiﬁcant
(F = 1.60, df = 1,61, p = 0.21).
Uncorrected  for age, the main effect of Genotype
became signiﬁcant (F = 4.18, df = 1,62, p = 0.045),with
RT being shorter in high-expressers (LaLa, RT
mean = 1709.8 ms,  SD = 503.6) than low-expressers
(S/Lg, RT mean = 1934.2 ms,  SD = 451.5). The main effect of
Diagnosis  and the Diagnosis by Genotype interaction were
not  signiﬁcant.
Complementary analyses used anxiety scores instead of
Diagnostic  groups. After age correction, the correlation of
RT  with SCAREDpc signiﬁcantly differed between Geno-
type  groups (F = 7.26, df = 1,62, p = 0.009). However, when
computed for each group separately, neither of the correla-
tions  of RT with anxiety was signiﬁcant. The low-expresser
group showed a non-signiﬁcant positive correlation, while
the  high-expresser showed a non-signiﬁcant negative cor-
relation.  Findings were similar with age uncorrected (main
effect  of Genotype: F = 6.89, df = 1,63; p = 0.01).
3.4. Reaction time (RT) and lambda
RT for valid trials across bet and pass trials and corrected
for age, was positively correlated with lambda (F = 4.8,
df  = 1,63, p = 0.032) (see Fig. 4). The more loss-averse the
participants were, the slower they were. This relationship
was not modulated by the type of selection (bet vs. pass;
decision*lambda, F = 1.86, df = 1,63, p = 0.18) or by anxiety
level  (SCAREDpc*lambda F = .20, df = 1,62, p = .65). For com-
pleteness, when not corrected for age, the correlation of
RT  with lambda became not signiﬁcant (F = 1.53, df = 1,63,
p  = 0.13).rRT) in the anxious and healthy groups by genotype (A-LaLa: anxious
rs; H-S/Lg: healthy low-expressers).
Finally, we repeated all previous analyses after adding
RT  as a nuisance covariate. The two-way ANCOVA with
age  and RT as covariates was still signiﬁcant for the Geno-
type*Diagnosis interaction on lambda (F = 4.04, df = 1,60,
p  = 0.049), the main effect of Genotype was a trend
(F = 3.65, df = 1,60, p = 0.06), and Diagnosis was not sig-
niﬁcant (F = 0.65, df = 1,60, p = 0.42). Findings were similar
when not correcting for age. After decomposing the Geno-
type*Diagnosis interaction by conducting an ANCOVA in
each  diagnostic group, ﬁndings were similar to when
uncorrected for RT, i.e., showing a signiﬁcant effect of Geno-
type  on lambda in the anxious group and no effect in the
healthy  group. Removing the age covariate did not modify
these  ﬁndings.
4.  Discussion
Our purpose was  4-fold, to (1) investigate loss aversion
in  adolescents, (2) compare levels of loss aversion between
clinically anxious and healthy adolescents, (3) examine the
modulation of loss aversion by the 5HTTPLR variation, (4)
particularly as a function of Diagnosis status.
First, we demonstrate that adolescents, like adults, are
more  sensitive to losses than gains. We  also show that
levels of loss aversion correlate with age, such that older
participants are more loss-averse than their younger coun-
terparts.  This latter age-related ﬁnding may  account to
some  extent for the relatively lower lambda mean score
of  1.4 in this group of adolescents when compared to
the  typical lambda of 2 described in adults who may
continue to grow more loss averse with age (Novemsky
and Kahneman, 2005). The potentially lower loss aversion
index  in adolescents relative to adults may  also reﬂect
the  higher level of risk-taking behavior in adolescence.
This ﬁnding is discrepant with the one study comparing
lambda in 18 adolescents (15.5 years old) and 16 adults (28
years  old) who  performed a variant of the mixed-gambles
task in the scanner (Barkley-Levenson et al., 2013). This
study  found a lower lambda than expected in adults, with
no  age-group differences (lambda adolescent mean = .99,
adult  mean = 1.1). This negative ﬁnding may  reﬂect the rel-
atively  small sample sizes. Alternatively, the ﬁnding could
relate  to the context in which the task was performed, i.e.,
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eclining in a scanner. Although a longitudinal study would
e  the most valid way to examine developmental changes
n  loss aversion, the present work in 66 adolescents estab-
ishes  the presence of a proclivity for loss aversion that
ncreases with age. For completeness, we also examined
ow the effect of age on loss aversion was modulated by
enotype and diagnostic status. These exploratory anal-
ses  revealed that the correlations of age with lambda
iffered signiﬁcantly by genotype, revealing a strong posi-
ive  correlation in high-expressers (LaLa) and no signiﬁcant
ssociation in low-expressers (S/Lg). Of note, mean age and
ge  range were similar in both genotype groups. In con-
rast,  diagnostic status did not modulate the relation of age
ith  lambda. Because of the relatively small number of sub-
ects,  it is premature to interpret these data, particularly in
he  absence of similar data in the literature. However, the
otential  role of SERT genotype on the development of loss
version  between ages 8 and 17 years could be examined in
elationship  to changes in impulsivity and risk-taking over
his  age range. The low-expression genotype (S), already
hown to potentially predispose to higher impulsivity (e.g.,
eitchman  et al., 2003; Curran et al., 2005; Manor et al.,
001;  Retz et al., 2008, 2002; Seeger et al., 2001; Zoroglu
t  al., 2002), might also contribute to risk-taking by being
ssociated with a lack of increase in loss aversion with age.
The  second main ﬁnding, against prediction, suggests
hat levels of loss aversion do not differ between highly
nxious and healthy adolescents. Furthermore, lambda was
ot  correlated with anxiety severity (SCAREDpc). This ﬁnd-
ng  is at odds with the expectation that loss aversion might
e  a facet of harm avoidance, a well-recognized feature
f  anxiety (Lorian and Grisham, 2010; Maner et al., 2007;
ueller et al., 2010). The next set of ﬁndings may  shed light
n  this surprising result by suggesting that the absence of
iagnostic-group differences might be related to the vari-
bility  of loss aversion across anxious individuals, which
dentiﬁes a subgroup of risk-prone anxious adolescents, as
escribed  in previous work (Erwin et al., 2003; Kachin et al.,
001;  Kashdan et al., 2006, 2008; Kashdan and Hofmann,
008). lambda residuals (controlled for age, rlambda) across the whole sample
Our  third and fourth questions are clariﬁed by the
signiﬁcant interaction of Diagnosis (anxious vs. healthy)
by  Genotype (high- vs. low-expresser) on lambda and
RT.  These two  interactions indicate that the SERT geno-
type  modulates lambda and RT in anxious patients, but
not  in healthy adolescents. The anxious adolescents who
are  also high-expressers (LaLa) execute their decision sig-
niﬁcantly  faster than the other three groups, suggesting
that these adolescents also manifest impulsivity. Taken
together, these ﬁndings identify a subgroup of anxious ado-
lescents  who, by virtue of their genotype (5HTTLPR LaLa
high-expression), appears to be distinctly low in risk aver-
sion,  and fast in making a decision between risky and
safe options. The low-expression (S/Lg carriers) anxious
group did not differ from the other two  healthy sub-
groups, who  themselves did not differ from one another.
The  group of anxious adolescents, homozygous carriers of
the  high-expression 5HTTPLR alleles, and who  manifest
loss-insensitivity (low lambda) and impulsivity (fast reac-
tion  time) may  represent a subgroup of anxious individuals
who are vulnerable to comorbid disorders associated with
impulsivity and risky decision, such as substance abuse
(Compton et al., 2007; Pasche, 2012). Such comorbid-
ity signiﬁcantly worsens prognosis and adds substantial
complexity to the treatment of anxiety disorders. Conceiv-
ably,  this risk-taking anxious subgroup may  not respond
optimally to pharmacotherapy with Selective Serotonin
Reuptake Inhibitors. This notion could be critical for treat-
ment  planning. However, much work is still needed to
validate this subgroup before applying this ﬁnding to clin-
ical  practice.
A  number of limitations need to be considered. First,
when decomposed by Diagnosis (anxious, comparison) and
Genotype  (high-expressers, low-expressers), the sample
sizes  become relatively small, which may  have limited our
power  to detect signiﬁcant effects, such as higher loss aver-
sion  in low-expresser anxious individuals relative to the
healthy  group. However, despite this limitation, a signiﬁ-
cant  genotype by diagnosis interaction effect was  observed,
which was particularly relevant to the question regarding
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risk factors for comorbid externalizing disorders in anxious
adolescents. Nevertheless, this ﬁnding should be viewed
with  caution, since the likelihood of spurious ﬁndings also
increases  with small sample sizes. Second, the anxious
group included adolescents diagnosed with a variety of
anxiety  disorders, which, while matching the most typical
presentation of clinical anxiety (Kessler and Wang, 2008;
Merikangas and Kalaydjian, 2007; Swinbourne et al., 2012)
may  have introduced noise to the data. However, such
diagnostic heterogeneity might have resulted in provid-
ing  data on a core behavioral substrate of anxiety present
across the various disorders. For completeness, we  never-
theless  conducted an exploratory ANOVA comparing GAD
(n  = 16), SocPh (n = 7) and SAD (n = 11) patients, and found
no  Diagnosis effects on lambda or reaction time (results not
shown).  Third, age differed signiﬁcantly across groups, and
was  correlated with lambda, our main variable of interest.
Although we  controlled for age in all analyses, the group
difference in age remains a limitation, as we may  not have
been  able to control for potential non-linear effects of age.
Finally,  the implication of the present ﬁndings for sub-
stance abuse vulnerability cannot be directly assessed in
this  study of young adolescents, because substance use was
an  exclusion criterion.
Despite  these limitations, as a preliminary study, the
present ﬁndings can inform future work that begins to
probe  the neurobiology of a subset of anxiety disorders
potentially at risk for severe comorbid disorders related to
risk-taking  and impulsivity.
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